ATLANTIS SG 2000

Methods	Country: UK Setting/Design: Multicentre Time frame: NS Randomisation method: NS Blinding ‐ Participants: No ‐ Investigators: No ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: Yes Follow‐up period: 24 months Loss to follow‐up: 42
Participants	Inclusion criteria DM: Type 1 Microalbuminuria: 20‐200 µg/min in 2 of 3 collections Untreated BP: < 150/90 mm Hg for patients < 50 years and < 165/90 mm Hg for patients 50‐65 years Ramipril group 1 Number: 47 Age: 44 (11) Sex (M/F): 44/3 Ramipril group 2 Number: 45 Age: 40 (13) Sex (M/F): (44/1) Placebo group Number: 48 Age: 40 (12) Sex (M/F): 46/2 Exclusion criteria Pregnant or lactating Women of child‐bearing potential and not using adequate contraception Concomitant therapy for hypertension Treatment one or more NSAIDs History of drug or alcohol abuse Other known renal diseases or raised Creatinine levels > 120 μmol/L) Liver function twice that of normal on repeat testing Iodine sensitivity
Interventions	Ramipril group 1 25 mg/d Ramipril group 2 5 mg/d Placebo group Co‐interventions: No
Outcomes	AER BP GFR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate